Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.

Bonnie RamseyChristoph U CorrellDavid R DeMasoEdward F McKoneElizabeth TullisJennifer L Taylor-CousarChenghao ChuNataliya VolkovaNeil AhluwaliaDavid WaltzSimon TianMarcus Alexander Mall

Published in: American journal of respiratory and critical care medicine (2023)

Our review of data from clinical trials, post-marketing reports, an ongoing registry-based ELX/TEZ/IVA post-authorization safety study, and peer-reviewed literature suggests depression symptoms and depression-related events reported in pwCF treated with ELX/TEZ/IVA are generally consistent with background epidemiology of these events in CF population, and do not suggest a causal relationship with ELX/TEZ/IVA treatment.

Keyphrases

clinical trial
depressive symptoms
cystic fibrosis
sleep quality
randomized controlled trial
risk factors
big data
physical activity
replacement therapy
deep learning
artificial intelligence
newly diagnosed